Pyogenic granuloma in children: treatment with topical imiquimod.
We report the successful treatment of five children with facial pyogenic granuloma using topical imiquimod 5% cream. In all cases, resolution of the lesions was achieved within 2-4 weeks. Local erythema and scaling, consistent with a typical imiquimod response, was the most commonly observed side effect. No systemic complications were observed in any of the patients. There has been no recurrence of any of the lesions to date. Small mildly erythematous or hypopigmented macules remain at this stage of follow up.
Fallah
Haady
H
Concord Repatriation General Hospital, Concord, New South Wales, Australia. haady@mail.com
Fischer
Gayle
G
Zagarella
Samuel
S
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects; D000287:Administration, Topical; D000634:Aminoquinolines / Q000008:administration & dosage* / Q000009:adverse effects; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D002675:Child, Preschool; D005145:Face / Q000473:pathology; D005260:Female; D017789:Granuloma, Pyogenic / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077271:Imiquimod; D007223:Infant; D008297:Male; D012867:Skin / Q000473:pathology
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D020533:Angiogenesis Inhibitors; D000077271:Imiquimod